# Mebendazole Overview

**Mebendazole** is best known as an over-the-counter anti-parasitic medicine, but it is now attracting serious interest as a **multi-target repurposed cancer therapy**. In oncology research, it is relevant because it interferes with cell division, blocks angiogenesis, disrupts cancer survival signalling, and may enhance anti-tumour immune activity.

### At a Glance

* **What it is:** A benzimidazole anti-parasitic drug being repurposed for cancer research
* **Why it matters:** It targets tubulin, angiogenesis, ERK/MAPK-related signalling, HIFs, Akt, NF-κB, and tumour metabolism
* **Best-supported use today:** Investigational adjunctive or repurposed-drug use, not standard-of-care replacement
* **Strongest evidence:** Broad preclinical evidence with early human safety and small clinical signals
* **Main limitation:** Human efficacy data remains early and not yet definitive

### Why mebendazole is studied in oncology

Mebendazole has moved beyond its original anti-parasitic role because it appears to affect multiple cancer hallmarks at once.

Research suggests it may:

* inhibit tubulin polymerisation and disrupt mitosis
* suppress angiogenesis through VEGFR2-related effects
* interfere with Akt, NF-κB, β-catenin, and HIF-related signalling
* reduce metastatic behaviour in selected models
* support anti-tumour immunity through context-dependent ERK effects
* work as a useful partner in drug-repurposing strategies

### Clinical Positioning

Current evidence best supports mebendazole as an **investigational repurposed adjunct** rather than a proven cancer therapy.

Its strongest current relevance is in the overlap between:

* low-cost repurposed-drug interest
* anti-angiogenic and anti-mitotic strategies
* selected CNS and gastrointestinal cancer settings
* combination protocols under clinician supervision

### Evidence Quality Rating

**3.5/5 — Moderate-to-strong preclinical evidence with emerging clinical data**

This rating reflects broad mechanistic and preclinical evidence, plus early human safety and biomarker data, but limited large interventional cancer trials.

### Where to Go Next

* [Evidence Summary](/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/evidence-summary.md)
* [Anticancer Mechanisms](/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/anticancer-mechanisms.md)
* [Evidence by Cancer Type](/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/mebendazole-evidence-by-cancer-type.md)
* [Immune Effects](/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/immune-effects.md)
* [Pharmacokinetics & Dosing](/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/pharmacokinetics-and-dosing.md)
* [Safety & Interactions](/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/safety-and-interactions.md)
* [Sourcing Quality Mebendazole](/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/sourcing-quality-mebendazole.md)

**See also:** [Mebendazole and TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/mebendazole-and-tp53.md)

### Key References

Mebendazole as a Candidate for Drug Repurposing in Oncology\
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/>

Emerging Perspectives on the Antiparasitic Mebendazole as a Cancer Therapy\
<https://pmc.ncbi.nlm.nih.gov/articles/PMC9862092/>

Repurposing Drugs in Oncology (ReDO)—mebendazole as an anti-cancer agent\
<https://ecancer.org/en/journal/article/443-repurposing-drugs-in-oncology-redo-mebendazole-as-an-anti-cancer-agent>

{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}

{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}


---

# Agent Instructions: Querying This Documentation

If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter:

```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/mebendazole-overview.md?ask=<question>
```

The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.